Lynch’s rhPDGF-BB IND secures FDA clearance for Phase II trial
The randomised, multi-centre, dose-ranging trial will assess the tolerability, safety, and early efficacy of rhPDGF-BB injection.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance